Wang Y, et al. - In ovarian cancer patients, researchers investigated overall survival (OS), disease-free survival (DFS) and adverse effects between hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) via a systematic review and meta-analysis using PubMed, Embase and Web of Science databases. In the overall analysis (13 studies), patients in the HIPEC group displayed a significantly improved OS and DFS. Outcomes suggest that administration of HIPEC + CRS can lead to significantly improved OS among ovarian cancer patients, even if optimal drug regimen was unclear.